Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for Periprosthetic Bone Loss Following Hip Replacement
NCT02444585Phase 1Withdrawn
- Sponsor
- University of Southern California
- Start
- Feb 2017
- Primary completion
- Dec 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in periprosthetic osteolysis (PPO) comparing Denosumab with Placebo (2 arms). Primary endpoint: Change in Bone Mineral Density in Gruen Zone 7 at 12 months. Planned start Feb 2017; status: withdrawn.
02
Drugs
denosumab
03
Conditions
periprosthetic osteolysis (PPO)
Beyond the preview
Go deeper on NCT02444585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02444585.